Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Nose virus may explain brain fog in long COVID

NCT ID NCT05220241

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at 51 adults who had COVID-19 2 to 12 months earlier and still had brain fog or other thinking problems. Researchers checked if the virus was still hiding in the nose's smell center. They compared these patients to a control group to see if lingering virus is linked to ongoing cognitive symptoms.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

51 people

The number who actually took part.

Started

Jul 2022

Finished

Jul 2025

Lead sponsor

A research network

The lead sponsor is a research network or cooperative group.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 60 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Common to cases and controls: * Age ≥ 18 years old and \<60 years old * Good oral and written command of French * Level of education ≥ 7 years of schooling * Initial episode of COVID-19 within 2 to 12 months * Symptomatic initial episode of COVID-19 * Initial symptoms not explained by another diagnosis * Initial episode documented by RT-PCR positive for SARS-CoV-2 and / or positive antigen test and / or positive serology (in the absence of vaccination) * Express consent to participate in the study * Affiliate or beneficiary of a social security scheme Case group: * Presence of at least one of the initial symptoms beyond 4 weeks following the onset of the acute phase of the disease * Prolonged symptoms not explained by another diagnosis with no known link to COVID-19 * Neurocognitive complaint (s) previously objectified by a neurologist and after completion of a neuro-psychological assessment * Impact of neurocognitive disorders on daily life authenticated by a Glasgow outcome scale extended ≤ 7 (see appendix 1) * Evolution of complaints for 2 to 12 months compared to the date of their first appearance Exclusion Criteria: Exclusion criteria common to cases and controls: * Person benefiting from a legal protection measure * Pregnant or breastfeeding woman * At least one neurological pathology among: * encephalopathy * encephalitis * severe neurological form of the initial episode of COVID-19 * neurodegenerative disease * History of stroke * Serious psychiatric history * Known nasal sinus pathology * Hemostatic disorder * Taking aspirin in the 15 days preceding the sample * Treatment with anticoagulants * Known allergy to lidocaine Secondary exclusion criteria for controls: \- Positive SARS-CoV-2 RT-PCR on nasopharyngeal sample on the day of inclusion

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cognitive disorder are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Hôpital Fondation A. de Rothschild

    Paris, 75019, France

  • Hôpital Lariboisière-Fernand-Widal

    Paris, 75010, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.